Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide
- PMID: 2733037
- DOI: 10.1093/jnci/81.12.935
Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide
Abstract
Canine osteosarcoma is a spontaneous malignancy in dogs, characterized by micrometastasis to pulmonary and extrapulmonary tissues at the time of diagnosis. Standard treatment involves amputation of the affected leg, but median survival time is 3-4 months with death due to metastasis. A randomized double-blind trial was conducted to evaluate liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (liposome/MTP-PE) as a treatment for metastasis in dogs undergoing amputation for osteosarcoma. Fourteen dogs were treated with liposome/MTP-PE, and 13 were treated with empty liposomes. Median survival time was 222 days for dogs treated with liposome/MTP-PE, compared to 77 days for dogs treated with empty liposomes (P less than .002). In the liposome/MTP-PE-treated group there were still four dogs alive and free of metastasis at greater than 1 year post surgery. Treatment was well tolerated; no significant toxic effects were noted except for mild elevations in body temperature (1-2 degrees C) for 2-6 hours post injection.
Similar articles
-
Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin.Clin Cancer Res. 1995 Dec;1(12):1595-601. Clin Cancer Res. 1995. PMID: 9815961 Clinical Trial.
-
Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma.Anticancer Res. 1998 Mar-Apr;18(2A):1015-9. Anticancer Res. 1998. PMID: 9615757
-
Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.Clin Cancer Res. 1999 Dec;5(12):4249-58. Clin Cancer Res. 1999. PMID: 10632367 Clinical Trial.
-
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.Hematol Oncol Clin North Am. 1995 Aug;9(4):927-38. Hematol Oncol Clin North Am. 1995. PMID: 7490249 Review.
-
Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.Cancer Treat Res. 1993;62:101-7. doi: 10.1007/978-1-4615-3518-8_14. Cancer Treat Res. 1993. PMID: 8096724 Review.
Cited by
-
Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma.Cancers (Basel). 2022 Dec 30;15(1):272. doi: 10.3390/cancers15010272. Cancers (Basel). 2022. PMID: 36612267 Free PMC article. Review.
-
Review of mifamurtide in the treatment of patients with osteosarcoma.Ther Clin Risk Manag. 2010 Jun 24;6:279-86. doi: 10.2147/tcrm.s5688. Ther Clin Risk Manag. 2010. PMID: 20596505 Free PMC article.
-
Mifamurtide: a review of its use in the treatment of osteosarcoma.Paediatr Drugs. 2010 Jun;12(3):141-53. doi: 10.2165/11204910-000000000-00000. Paediatr Drugs. 2010. PMID: 20481644 Review.
-
Prognostic factors in canine appendicular osteosarcoma - a meta-analysis.BMC Vet Res. 2012 May 15;8:56. doi: 10.1186/1746-6148-8-56. BMC Vet Res. 2012. PMID: 22587466 Free PMC article. Review.
-
Stem cell growth factor receptor in canine vs. feline osteosarcomas.Oncol Lett. 2016 Oct;12(4):2485-2492. doi: 10.3892/ol.2016.5006. Epub 2016 Aug 12. Oncol Lett. 2016. PMID: 27698817 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources